Movement Disorder News and Research

Latest Movement Disorder News and Research

Medtronic 2011 first quarter revenue decreases 4%

Medtronic, Inc. today announced financial results for its first quarter of fiscal year 2011, which ended July 30, 2010.

24 Aug 2010

TEMPO study recommends early administration of Azilect in PD patients

Teva Pharmaceutical Industries Ltd. and H. Lundbeck A/S (Lundbeck) today announced newly published long-term data on Azilect(rasagiline tablets) from the TEMPO study and its open-label extension. The findings confirm the long-term efficacy, safety and tolerability of Azilect® in patients with Parkinson's disease (PD) and further demonstrate the benefits obtained with early treatment initiation. The data was published in the June 2010 issue of the International Journal of Neuroscience.

6 Aug 2010

Medtronic launches Defeat-HF clinical trial to evaluate SCS for heart failure

Medtronic, Inc. today announced the global launch of the Defeat-HF (Determining the Feasibility of Spinal Cord Neuromodulation for the Treatment of Chronic Heart Failure) clinical trial. It is the industry's first prospective, randomized study evaluating the clinical feasibility of spinal cord stimulation, or neurostimulation, to improve clinical signs and symptoms of heart failure.

30 Jul 2010

Rotigotine provides clinically relevant improvements in RLS symptoms: Study

UCB today announced the results of a 6-month, randomized, double-blind, placebo-controlled clinical study, published in the journal Movement Disorders, showing that Neupro® (rotigotine transdermal system, 2 and 3 mg/24 hours) provided sustained, clinically relevant improvements in symptoms of Restless Legs Syndrome (RLS). The study also showed high rates of complete remission seen with rotigotine 2 mg or 3 mg/24 hours.

29 Jul 2010

Loss of key nerve cells cause Parkinson's disease: Research

Scientists at the Stanford University School of Medicine have identified a molecular pathway responsible for the death of key nerve cells whose loss causes Parkinson's disease. This discovery not only may explain how a genetic mutation linked to Parkinson's causes the cells' death, but could also open the door to new therapeutic approaches for the malady.

29 Jul 2010

Patients with advanced Parkinson's disease prefer dopamine agonists, shows review

Of the three main types of oral drugs commonly added to levodopa therapy for patients with advanced Parkinson's disease, one might be the most effective, according to a new review.

9 Jul 2010

Scientists identify new strategy for treating movement disorders

Scientists at the Gladstone Institute of Neurological Disease and Stanford University have shown how key circuits in the brain control movement. The research, published in the journal Nature not only establishes the function of these circuits, but offers promise for treating movement related disorders, such as Parkinson's disease.

8 Jul 2010

Experts to discuss latest advancements in neurological disorders at Neurorehabilitation Symposium

Scientists and engineers from around the globe will gather in August to share new information regarding neurorehabilitation advances for people with neurological movement disorders, including spinal cord and brain injures.

2 Jul 2010

University College London neurology professor becomes first recipient of Lord Brain Memorial Medal

Andrew Lees, Professor of Neurology at University College London, is to be the first ever recipient of the Lord Brain Memorial Medal - awarded for the scientific contributions he has made to the field of movement disorders within the UK. He will receive the medal following his delivery of the inaugural Lord Brain Memorial Lecture; "Brainwashed by the Black Stuff," at Barts and The London Medical School on June 24, 2010.

1 Jul 2010

Mutation in ion channel that changes its dynamics is implicated in epilepsy: Scientists

In 2004, Washington University in St. Lous researcher Jianmin Cui was handed a puzzling clue to the structure of an ion channel his lab had been studying for five years.

24 Jun 2010

MJFF supports Ceregene's CERE-120 Phase 2 study for PD with $2.5M award

The Michael J. Fox Foundation for Parkinson's Research (MJFF) will provide $2.5 million to support Ceregene Inc.'s new Phase 2 study of CERE-120. This novel gene therapy product delivers the gene for neurturin, a potent neurotrophic (growth) factor that has shown potential to improve the status of degenerating neurons in both preclinical and clinical studies. CERE-120 has the potential to improve motor function as well as slow Parkinson's disease (PD) progression.

23 Jun 2010

Neupro improves wellbeing impaired by pain related to Restless Legs Syndrome

The first data to show that Neupro® (rotigotine transdermal system) significantly improved wellbeing and daily activities that are often impaired by pain related to Restless Legs Syndrome (RLS) were presented this week at the 14th International Congress of Parkinson's Disease and Movement Disorders in Buenos Aires, Argentina.

18 Jun 2010

Study finds anxiety/panic disorder as most-disabling psychiatric disorder associated with TS

An assessment of patients with adult Tourette syndrome (TS) to identify clinical factors that contribute to psychosocial and occupational disabilities resulting from the vocal or motor tics that define TS found that anxiety/panic disorder may be the most disabling psychiatric condition associated with the disorder.

18 Jun 2010

Chelsea presents Northera study data at International Congress on Parkinson's Disease and Movement Disorders

Chelsea Therapeutics International, Ltd. announced that data from its pivotal studies of Northera™ (droxidopa) in symptomatic neurogenic orthostatic hypotension was presented during a poster session and featured in a symposium highlighting the role of norepinephrine (NE) deficiency in Parkinson's disease at the 14th International Congress on Parkinson's Disease and Movement Disorders in Buenos Aires, Argentina.

17 Jun 2010

Prevalence of GID in PD patients has impact on clinical and societal outcomes: Study

New data from a retrospective cohort study showed that up to three quarters of patients with Parkinson's disease developed gastrointestinal disorders that can have a substantial adverse effect on major PD-related clinical and health economic outcomes. These data were presented at the 14th International Congress of Parkinson's Disease and Movement Disorders in Buenos Aires, Argentina (June 13-17, 2010).

16 Jun 2010

Study confirms Azilect as a selective MAO-B inhibitor

Teva Neuroscience Inc. today announced the publication of a study demonstrating the selectivity of Azilect® (rasagiline tablets) for inhibition of MAO-B (monoamine oxidase-B) at the maximum approved dose of 1 mg/day. The data was published in the Journal of Clinical Pharmacology OnlineFirst on May 5, 2010.

4 Jun 2010

U-M researchers one step closer to discovering why certain diseases affect specific organs

Why do some diseases affect only specific organs, leaving others invulnerable? Researchers from the University of Michigan have found neural tissue contains imbalanced levels of proteins, which may explain the brain's susceptibility to a debilitating childhood movement disorder.

3 Jun 2010

Research explains brain's susceptibility to dystonia

3 Jun 2010

DBS procedure effective for treating Parkinson's disease

Studies have shown that a "brain pacemaker" called deep brain stimulation (DBS) is an effective treatment for Parkinson's disease.

3 Jun 2010

Researchers use CASL MRI technique to map cerebral blood flow patterns in schizophrenic patients

Researchers in Germany have used a magnetic resonance imaging technique called continuous arterial spin labeling to map cerebral blood flow patterns in schizophrenic patients quickly and without using radiation or contrast agents. Their findings appear in the online edition and July printed issue of the journal Radiology.

26 May 2010

Movement Disorder News and Research

Latest Movement Disorder News and Research

Medtronic 2011 first quarter revenue decreases 4%

TEMPO study recommends early administration of Azilect in PD patients

Medtronic launches Defeat-HF clinical trial to evaluate SCS for heart failure

Rotigotine provides clinically relevant improvements in RLS symptoms: Study

Loss of key nerve cells cause Parkinson's disease: Research

Patients with advanced Parkinson's disease prefer dopamine agonists, shows review

Scientists identify new strategy for treating movement disorders

Experts to discuss latest advancements in neurological disorders at Neurorehabilitation Symposium

University College London neurology professor becomes first recipient of Lord Brain Memorial Medal

Mutation in ion channel that changes its dynamics is implicated in epilepsy: Scientists

MJFF supports Ceregene's CERE-120 Phase 2 study for PD with $2.5M award

Neupro improves wellbeing impaired by pain related to Restless Legs Syndrome

Study finds anxiety/panic disorder as most-disabling psychiatric disorder associated with TS

Chelsea presents Northera study data at International Congress on Parkinson's Disease and Movement Disorders

Prevalence of GID in PD patients has impact on clinical and societal outcomes: Study

Study confirms Azilect as a selective MAO-B inhibitor

U-M researchers one step closer to discovering why certain diseases affect specific organs

Research explains brain's susceptibility to dystonia

DBS procedure effective for treating Parkinson's disease

Researchers use CASL MRI technique to map cerebral blood flow patterns in schizophrenic patients

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Movement Disorder News and Research

Latest Movement Disorder News and Research

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Newsletters you may be interested in